+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07040098

Phase II Study Comparing Four Neoadjuvant Immunotherapy and Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer

Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-06-26

228

Participants Needed

2

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the best ways to combine immunotherapy with neoadjuvant chemoradiotherapy for patients with locally advanced rectal cancer. This phase II, prospective, multicenter, randomized trial aims to address key uncertainties such as the timing of radiotherapy and chemotherapy, the number of chemotherapy cycles, and the optimal radiotherapy mode. The study seeks to find treatment strategies that improve tumor response, preserve organ function, and enhance quality of life for patients. Participants are assigned to one of four treatment groups combining short-course or long-course radiotherapy with varying cycles of chemotherapy and the PD-1 inhibitor Sintilimab. The short-course radiotherapy groups receive 5 Gy for 5 sessions followed by either four or six cycles of chemotherapy and immunotherapy. The long-course groups receive 50 Gy in 25 fractions with concurrent capecitabine, followed by four or six cycles of chemotherapy and immunotherapy. After treatment, patients may undergo surgery or choose a watch-and-wait strategy if complete remission is achieved. During the study, researchers will assess the complete response rate two months after therapy or shortly after surgery, along with tumor regression, acute toxicities, surgical complications, survival rates, organ preservation, anal function, and quality of life over a three-year follow-up. Patients will have multiple assessments at baseline, post-treatment, and at intervals up to three years to evaluate safety and long-term outcomes. The study is sponsored by the Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

CONDITIONS

Brief Title

Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

Research Team

Y

Yuan Tang

X

Xiao Qin

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here